

Synthesis and Evaluation of Bithiazole Derivatives As Potential α -Sarcoglycan Correctors

Giovanni Ribaudò, Marcello Carotti, Alberto Ongaro, Erika Oselladore, Martina Scano, Giuseppe Zagotto, Dorianna Sandonà,* and Alessandra Gianoncelli*



Cite This: <https://doi.org/10.1021/acsmmedchemlett.3c00046>



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: 4'-Methyl-4,5'-bithiazoles were previously identified as cystic fibrosis transmembrane regulator (CFTR) correctors, thus being able to correct folding defective mutants of the channel regulating chloride transport through the membrane. Additionally, bithiazole derivative C17 was reported to recover α -sarcoglycan *in vitro* and *in vivo*. We report here the synthesis of two new derivatives of C17, in which the two sides of the bithiazole scaffold were modified. The synthesized compounds and the corresponding precursors were tested in myogenic cells to evaluate the expression of α -sarcoglycan. The results highlighted that both substitutions of the bithiazole scaffold are important to achieve the maximum recovery of the α -sarcoglycan mutant. Nonetheless, partial preservation of the activity was observed. Accordingly, this paves the way to further derivatizations/optimization and target fishing studies, which were preliminarily performed in this study as a proof of concept, allowing the investigation of the molecular mechanisms leading to the α -sarcoglycan correction.

KEYWORDS: bithiazole, α -sarcoglycan, CFTR, myotubes



AlphaFold structure prediction of α -sarcoglycan

Thiazole is a five-membered ring bearing two heteroatoms, consisting of one sulfur atom and one nitrogen atom at positions 1 and 3. Compounds based on this scaffold show diverse biological activities translated into molecules of pharmacological interest.¹

Antibacterial, antifungal, antiparasitic, antiulcer, anti-inflammatory, and antiproliferative effects are only a portion of reported effects for thiazole-based small molecules. Additionally, compounds bearing two thiazole rings, separated by linkers or by a single bond such as bleomycin, have been approved as antiviral, antibacterial, and anticancer agents.² This class of compounds is constantly attracting the interest of medicinal chemists, and derivatives bearing two thiazole rings were recently reported to show multitarget anticancer activity.³

In previous reports, 4'-methyl-4,5'-bithiazoles were identified as cystic fibrosis transmembrane regulator (CFTR) correctors, i.e., compounds able to correct some folding defective mutants of the channel responsible for the control of chloride transport across the plasma membrane of many cell types.⁴ Structure–activity relationship (SAR) studies were conducted through the introduction of different substituents in this scaffold, guiding the identification of most the substituents leading to optimal bioactivity.⁵ In this respect, a compound named C17 emerged as one of the most promising lead compounds (Figure 1A).^{5–8}

This derivative was also tested for its ability to recover folding defective mutants of proteins other than CFTR such as the I661T mutant of ATP8B1, a protein belonging to the ABC transporter family that lacks homology with CFTR.⁹ More recently, C17 efficacy was evidenced in *in vitro* and *in vivo* models of the limb girdle muscular dystrophy R3 (LGMDR3), a rare genetic disease caused by mutations of the α -sarcoglycan protein.^{10,11} In both heterologous cell models and LGMDR3 myogenic cells, derived from a subject carrying missense mutations on the α -sarcoglycan coding gene, the salvage of the mutated protein in terms of quantity and localization was observed. Notably, in the humanized mouse model expressing the R98H- α -sarcoglycan, recovery of the defective protein corresponded to improvement in muscle strength.^{12–14} Thus, the 4'-methyl-4,5'-bithiazole derivatives, first screened for the treatment of cystic fibrosis, seemed to hold a promiscuous action, being able to recover proteins, different in terms of structure, but sharing with CFTR a similar fate when carrying missense mutations. Because of this feature, C17 and

Received: February 8, 2023

Accepted: July 26, 2023




Figure 1. (A) Chemical structure of C17. (B) Synthetic scheme and reaction conditions for the preparation of compound 5: (a) ethanol; (b) pivalic acid, DCC, DMAP, dichloromethane; (c) HBr, acetic acid, pyridinium tribromide; (d) thiourea, ethanol; (e) 6-(Boc-amino)hexanoic acid, CDI, DMF; (f) TFA, dichloromethane. (C) Synthetic scheme and reaction conditions for the preparation of compound 7: (g) 6-(Boc-amino)hexanoic acid, DMF, DIPEA, TBTU; (h) TFA, dichloromethane.




Figure 2. (A) Representative Western blot for the analysis of the α -sarcoglycan (α -SG) content in cells from a LGMDR3 subject carrying the L31P/V247 M α -SG mutations. Cells were differentiated for 7 days and treated for the last 72 h with either 1% DMSO (vehicle), the different compounds (cmp), or C17 at the indicated concentrations. Both anti α -sarcoglycan and β -actin antibodies were used, the last one for normalizing the content of loaded proteins. The red ponceau staining of the membrane is reported for reference. (B) The graph reports the densitometric analysis of independent WB experiments. The α -SG content is expressed as the fold increase of the amount present in the vehicle treated myotubes, the mean value \pm SD of a minimum four independent experiments, each one done in duplicate/triplicate, is also reported. Statistical analysis was performed by a one-way ANOVA test followed by multiple comparison Tukey's test; ns, $p > 0.05$, * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$. Boc- and Fmoc-protected precursors of compound 7 were also tested, and the results are reported in Figure S10 in the Supporting Information.

derivatives cover an interesting role in the field of protein misfolded diseases that surely deserves to be further studied, also identifying their specific interactor(s) and providing optimized compounds.

In this context, more recent studies aimed at investigating the efficacy of constrained bithiazoles that showed higher maximum efficacy in cystic fibrosis cells, however without significant enhancement of potency.^{8,15} Additionally, Martina

et al. very recently reported a SAR study based on bithiazole derivatives inspired by CFTR correctors aiming at the identification of multifunctional antibacterial agents.¹⁶

Here, the scaffold of the corrector C17 has been modified, introducing a suitable linker for future resin functionalization useful for chromatographic experiments aiming at the capture of the compound interactor(s),¹⁷ and the activity of the

obtained compounds in influencing α -sarcoglycan expression by myotubes was tested.

In this work, we describe the synthesis of two previously undisclosed derivatives of C17, in which the substituents on the two sides of the bithiazole scaffold were alternatively substituted with a linker terminating with an amino group.

The preparation of compound 5 was based on the procedure reported by Davison et al. for steps a–d (Figure 1B), with small modifications.¹⁸ Briefly, 3-chloro-2,4-pentandione was reacted with thiourea to provide compound 1, which was converted to compound 2 upon reaction with pivalic acid. Bromination with HBr, acetic acid, and pyridinium tribromide afforded compound 3 and another reaction with thiourea led to the isolation of compound 4. Compound 5 was then obtained by reaction with 6-(Boc-amino)hexanoic acid, and the intermediate was then deprotected through treatment with TFA to give the final compound. Preparation of compound 7 was straightforward (Figure 1C) and was achieved by reaction of the commercially available intermediate 6 with 6-(Boc-amino)hexanoic acid, followed by deprotection with TFA. The final compounds were characterized by NMR, mass spectrometry, and HPLC (Figures S1–S8 in the Supporting Information). The synthesis of compound 7 can also be achieved through the Fmoc protection strategy, starting from derivatization of compound 6 with 6-(Fmoc-amino)hexanoic acid, but lower yields were obtained in our attempts (data not shown).

The amino moieties introduced with this synthesis could be exploited for further derivatizations or for the immobilization of the ligands in the context of ligand–target interaction studies, such as those based on surface plasmon resonance (SPR), affinity chromatography, or probing/labeling, thus assessing the contribution of the different portions of C17 to the biological activity to aid the investigation of the underlying molecular mechanisms.

For 5 and 7, relevant physicochemical descriptors were calculated using SwissADME, and the drug-likeness of the synthesized compounds was preliminarily assessed.^{19,20} Overall, compounds 5 and 7 can be defined as druglike molecules, even if slightly high flexibility and polarity values were computed when compared to ideal features for pharmacokinetic parameters (Figure S9 in the Supporting Information). Moreover, based on the computed physicochemical descriptors, the compounds are predicted to be partially absorbed through the gastrointestinal tract, without crossing the blood–brain barrier.

Thus, we tested compounds 4, 5, 6, and 7 in the myogenic cells described above, comparing their effectiveness with the one of the lead compounds, C17. After treatment for 72 h, cells were lysed, proteins were resolved by SDS PAGE, and the content of α -sarcoglycan was analyzed by Western blot (WB; Figure 2).

Preliminary SAR information can be deduced from the results of the experiments. As expected, C17 at both 20 and 15 μ M (the concentration used in all previous experiments), elicited the maximum effect, doubling the content of the mutated α -sarcoglycan expressed by myotubes.^{12,13} The novel chemical entities maintained part of the activity, even though lacking either the substituted phenyl moiety, in the case of compound 4, or the *tert*-butyl moiety, in the case of compound 6. Indeed, the α -sarcoglycan rescue was significantly higher than the control, consisting of cells treated with the vehicle, both globally (Figure 2) and when the membrane fraction was

analyzed (Figure S11 in the Supporting Information) for both molecules. It must be noted that the tested compounds were demonstrated to be less effective than the original molecule C17, suggesting that both modifications are detrimental. Nevertheless, data on a wider set of compounds bearing modifications in terms of chain length, composition, position on the scaffold, and ramification or substitution would be needed to fully assess the significance in terms of the SAR of such variations.

On the other hand, the presence of the long hydrophobic chain in compound 7 did not affect activity drastically, and this holds true also for other precursors of compound 7 bearing the same hydrophobic chain that were studied, as reported in the Supporting Information. This is an ideal condition for the potential application of the compounds for the functionalization of resins in the context of target fishing studies, where the long hydrophobic chain can serve to pull the active part of the molecule away from the beads, thereby reducing steric hindrance during the binding of interactors.

In this context, a preliminary target fishing experiment, carried out using beads functionalized with compound 5 and compound 7 following a protocol reported in the literature,^{17,21} evidenced the ability of both derivatized resins to recover several protein interactors (Figure S12 in the Supporting Information). This experiment was intended as a proof of concept, and notably, some of the proteins were clearly displaced when the resins were incubated with an excess of free C17 molecule before the elution step, promisingly suggesting the presence of specific C17 interactors among the retrieved proteins.

In conclusion, according to these results, it is possible to infer that, besides the bithiazole core, both substituted moieties should be present to guarantee the maximum recovery of the α -sarcoglycan mutant. On the other hand, the preservation of part of the activity of the original molecule allows us to be confident that these derivatives may serve as useful tools for the identification of possible C17 interactors in target fishing experiments and for the clarification of its mechanism of action in sarcoglycanopathy.

Overall, this information is of major importance for the possibility of derivatizing C17, paving the way for mechanistic studies, and guiding further optimization of the compound.

EXPERIMENTAL PROCEDURES

Chemistry. Commercially available chemicals were purchased from Sigma-Aldrich and used without further purification. NMR experiments were performed on Bruker Avance III and Bruker Ascend spectrometers (frequencies: 400.13 and 100.62 MHz for ¹H and ¹³C, respectively; Bruker, Billerica, MA). For data processing, TopSpin 4.1.4 and iNMR 6.4.5 (Nucleomatica, Molletta, Italy) were used, and the spectra were calibrated using a solvent signal. Mass spectra were recorded by direct infusion electrospray (ESI) on an LCQ Fleet ion trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA) and on a Xevo G2 QTof high-resolution mass spectrometer (HRMS; Waters, Milford, MA). For data processing, the Qual Browser Thermo Xcalibur 4.0.27.13 software was used. The purity profile was assayed by HPLC using a Pro-Star system (Palo Alto, CA) equipped with a 1706 UV–vis detector (Bio-Rad, Hercules, CA) and a C-18 column (5 μ m, 4.6 \times 150 mm; Agilent, Santa Clara, CA). An appropriate gradient of 0.1% formic acid (A) and acetonitrile (B) was used as the mobile phase with an overall flow rate of 1 mL min⁻¹. The general methods for the analyses are reported in the following.

Method for compound 5: 0 min (90% A–10% B), 1 min (90% A–10% B), 9 min (5% A–95% B), 12 min (5% A–95% B), and 13 min (90% A–10% B). Method for compound 7: 0 min (90% A–10% B), 2

min (90% A–10% B), 10 min (5% A–95% B), 14 min (5% A–95% B), and 16 min (90% A–10% B). Analyses were performed at 254 nm, and the purity profile was above 95% for final compounds (area %). Detailed synthetic procedures are described in the [Supporting Information](#). Throughout the experiments, no unexpected or unusually high safety hazards were encountered. In the [Supporting Information](#), ^1H NMR, ^{13}C NMR, ESI-MS spectra, and HPLC chromatograms are reported for final compounds ([Figures S1–S8](#)).

Prediction of Physicochemical Descriptors. Physicochemical descriptors considered to be relevant for drug-likeness, ADME parameters, and pharmacokinetic properties were predicted for compounds **5** and **6** using SwissADME (www.swissadme.ch, accessed on November 1, 2022, Molecular Modeling Group - Swiss Institute of Bioinformatics, Lausanne, CH).^{19,20} Results were plotted as radar graphs reporting the ideal chemical space for oral bioavailability, according to lipophilicity, size, polarity, solubility, insaturation, and flexibility scores of the molecules.

Cell Growth, Differentiation, and Treatments. Primary myogenic cells from a LGMDR3 subject (compound heterozygote for the V247 M and L31P mutations in the α -sarcoglycan protein)²² were grown in proliferation medium (PM) composed by DMEM (Sigma-Aldrich, St. Louis, MO, USA), at pH 7.2 supplemented with 30% Foetal Bovine Serum (FBS, Thermo Fisher Scientific, Waltham, MA, USA), 10 $\mu\text{g}/\text{mL}$ insulin, Fibroblast Growth Factor (FGF, 25 ng/mL), and Epidermal Growth Factor (EGF, 10 ng/mL; Sigma-Aldrich, St. Louis, MO, USA). Myotube differentiation was induced by replacing PM with differentiating medium (DM) composed of DMEM supplemented with 2% Horse Serum (Euroclone, Milano, Italy), 10 $\mu\text{g}/\text{mL}$ human recombinant insulin (Sigma, St. Louis, MO, USA), and 100 $\mu\text{g}/\text{mL}$ human transferrin (Sigma-Aldrich, St. Louis, MO, USA). Differentiation was carried out for 7 days. Treatments with compounds were carried out during the last 72 h of differentiation by the addition of vehicle (DMSO 1 %) or the different compounds dissolved in DMSO (final concentration 1%). At the end of the treatments, myotubes were washed twice with ice-cold PBS and then lysed with RIPA buffer (Tris-HCl 50 mM at pH 7.5, NaCl 150 mM, NP-40 1% v/v, sodium deoxycholate 0.5% w/v, SDS 0.1% w/v) supplemented with complete protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA).

Western Blot Analysis. Protein concentration in total protein lysates was determined with a BCA assay (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. Equal amounts of total proteins were separated by SDS-PAGE and transferred to a nitrocellulose membrane by semidry blotting. Membranes were blocked with 5% w/v skim milk in TBS-T buffer and probed with rabbit monoclonal anti- α -sarcoglycan (AB189254 from Abcam, Cambridge, UK) and mouse monoclonal anti- β -actin (Sigma-Aldrich, St. Louis, MO, USA); secondary antibodies were horseradish peroxidase-conjugated. Blots were developed with ECL chemiluminescent substrate (Euroclone, Milano, Italy), and chemiluminescent signals were digitally acquired with the Alliance Mini HD9 Imaging System (Uvitec, Cambridge, UK). Densitometry was performed with ImageJ software. The intensities of the α -sarcoglycan bands were normalized for the intensity of the Ponceau Red staining of the total protein loaded and for the intensity of the β -actin signal.

Biotinylation of Surface Proteins. For the biotinylation reaction, at the end of the treatment, myotubes were incubated at 4 °C for at least 10 min, and all of the procedures were performed at this temperature to slow down cellular processes preventing the internalization of biotin. Cells were then washed three times with ice cold PBS supplemented with calcium and magnesium and incubated under gentle agitation with a solution of 0.5 mg/mL biotin (EZ-Link Sulfo-NHS-LC-Biotin, Thermo Fisher) in PBS for 20 min at 4 °C. The biotinylation reaction was stopped, washing cells twice with 100 mM glycine in PBS (each wash 5 min) and twice with PBS. Cells were lysed with RIPA buffer, and lysates were centrifuged 30 min at 20 000g at 4 °C. The supernatants were quantified by BCA assay, and 50 μg of proteins were incubated with streptavidin agarose resin (Thermo Fisher, 30 μL of resin for each sample) overnight at 4 °C. The streptavidin resin, after the incubation under gentle rotation with

myotube lysates, was washed three times with RIPA buffer. Bound proteins were eluted with Laemmli sample buffer and analyzed by Western blot. The absence of biotin internalization was assessed by probing the Western blot membranes with an antibody specific for the cytosolic protein β -actin.

Statistical Analysis. Values are expressed as means \pm SD; statistical differences among groups were then determined by a one-way ANOVA test, followed by either Tukey's test for simultaneous multiple comparisons or a Dunnett test for simultaneous multiple comparisons with a control. A level of confidence of $p < 0.05$ was considered for statistical significance.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsmmedchemlett.3c00046>.

Synthetic procedures, NMR and ESI-MS spectra, HPLC chromatograms, results of computational studies, and additional Western blot data ([PDF](#))

■ AUTHOR INFORMATION

Corresponding Authors

Dorianna Sandonà – Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy;
Email: dorianna.sandona@unipd.it

Alessandra Gianoncelli – Department of Molecular and Translational Medicine, University of Brescia, 25121 Brescia, Italy; orcid.org/0000-0002-0816-5163;
Email: alessandra.gianoncelli@unibs.it

Authors

Giovanni Ribaudo – Department of Molecular and Translational Medicine, University of Brescia, 25121 Brescia, Italy; orcid.org/0000-0003-3679-5530

Marcello Carotti – Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy

Alberto Ongaro – Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy

Erika Oselladore – Department of Molecular and Translational Medicine, University of Brescia, 25121 Brescia, Italy; orcid.org/0000-0002-2546-1343

Martina Scano – Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy

Giuseppe Zagotto – Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy; orcid.org/0000-0001-7053-4196

Complete contact information is available at:
<https://pubs.acs.org/doi/10.1021/acsmmedchemlett.3c00046>

Author Contributions

Conceptualization, D.S. and G.Z.; methodology, G.R., M.C., A.O., M.S., and E.O.; validation, G.R. and M.C.; formal analysis, A.G.; investigation, G.R. and M.C.; data curation, G.R., M.C., D.S., and A.G.; writing—original draft preparation, G.R., M.C., and D.S.; writing—review and editing, D.S. and A.G.; supervision, D.S. and A.G.; project administration, D.S.; funding acquisition, G.R., D.S., and A.G.

Funding

The research was funded by University of Brescia to A.G. and G.R.; Association Française contre les Myopathies (AFM #23000) to D.S. and A.G.; the University of Padova to D.S.; and Fondazione Telethon (GGP20097) to D.S.

Notes

The authors declare no competing financial interest.

REFERENCES

- (1) Kerru, N.; Gummidi, L.; Maddila, S.; Gangu, K. K.; Jonnalagadda, S. B. A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications. *Molecules* **2020**, *25* (8), 1909.
- (2) Borcea, A.-M.; Ionuț, I.; Crișan, O.; Oniga, O. An Overview of the Synthesis and Antimicrobial, Antiprotozoal, and Antitumor Activity of Thiazole and Bisthiazole Derivatives. *Molecules* **2021**, *26* (3), 624.
- (3) Dawood, K. M.; Raslan, M. A.; Abbas, A. A.; Mohamed, B. E.; Abdellattif, M. H.; Nafie, M. S.; Hassan, M. K. Novel Bis-Thiazole Derivatives: Synthesis and Potential Cytotoxic Activity Through Apoptosis With Molecular Docking Approaches. *Front. Chem.* **2021**, *9*, 694870.
- (4) Lopes-Pacheco, M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. *Front Pharmacol* **2020**, *10*, 1662.
- (5) Yoo, C. L.; Yu, G. J.; Yang, B.; Robins, L. I.; Verkman, A. S.; Kurth, M. J. 4'-Methyl-4,5'-Bisthiazole-Based Correctors of Defective $\Delta F508$ -CFTR Cellular Processing. *Bioorg. Med. Chem. Lett.* **2008**, *18* (8), 2610–2614.
- (6) Kinting, S.; Höppner, S.; Schindlbeck, U.; Forstner, M. E.; Harfst, J.; Wittmann, T.; Griese, M. Functional Rescue of Misfolding ABCA3 Mutations by Small Molecular Correctors. *Hum. Mol. Genet.* **2018**, *27* (6), 943–953.
- (7) Dekkers, J. F.; Gogorza Gondra, R. A.; Kruijselbrink, E.; Vonk, A. M.; Janssens, H. M.; de Winter-de Groot, K. M.; van der Ent, C. K.; Beekman, J. M. Optimal Correction of Distinct CFTR Folding Mutants in Rectal Cystic Fibrosis Organoids. *Eur. Respir. J.* **2016**, *48* (2), 451–458.
- (8) Coffman, K. C.; Nguyen, H. H.; Phuan, P.-W.; Hudson, B. M.; Yu, G. J.; Bagdasarian, A. L.; Montgomery, D.; Lodewyk, M. W.; Yang, B.; Yoo, C. L.; Verkman, A. S.; Tantillo, D. J.; Kurth, M. J. Constrained Bisthiazoles: Small Molecule Correctors of Defective $\Delta F508$ -CFTR Protein Trafficking. *J. Med. Chem.* **2014**, *57* (15), 6729–6738.
- (9) van der Woerd, W. L.; Wichers, C. G. K.; Vestergaard, A. L.; Andersen, J. P.; Paulusma, C. C.; Houwen, R. H. J.; van de Graaf, S. F. J. Rescue of Defective ATP8B1 Trafficking by CFTR Correctors as a Therapeutic Strategy for Familial Intrahepatic Cholestasis. *Journal of Hepatology* **2016**, *64* (6), 1339–1347.
- (10) Angelini, C.; Fanin, M. Pathogenesis, Clinical Features and Diagnosis of Sarcoglycanopathies. *Expert Opinion on Orphan Drugs* **2016**, *4* (12), 1239–1251.
- (11) Vainzof, M.; Souza, L. S.; Gurgel-Giannetti, J.; Zatz, M. Sarcoglycanopathies: An Update. *Neuromuscular Disorders* **2021**, *31* (10), 1021–1027.
- (12) Carotti, M.; Marsolier, J.; Soardi, M.; Bianchini, E.; Gomiero, C.; Fecchio, C.; Henriques, S. F.; Betto, R.; Sacchetto, R.; Richard, I.; Sandonà, D. Repairing Folding-Defective α -Sarcoglycan Mutants by CFTR Correctors, a Potential Therapy for Limb-Girdle Muscular Dystrophy 2D. *Hum. Mol. Genet.* **2018**, *27* (6), 969–984.
- (13) Carotti, M.; Scano, M.; Fancello, I.; Richard, I.; Risato, G.; Bensalah, M.; Soardi, M.; Sandonà, D. Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery. *IJMS* **2020**, *21* (5), 1813.
- (14) Scano, M.; Benetollo, A.; Nogara, L.; Bondi, M.; Dalla Barba, F.; Soardi, M.; Furlan, S.; Akyurek, E. E.; Caccin, P.; Carotti, M.; Sacchetto, R.; Blaauw, B.; Sandonà, D. CFTR Corrector C17 Is Effective in Muscular Dystrophy, *in Vivo* Proof of Concept in LGMDR3. *Hum. Mol. Genet.* **2022**, *31* (4), 499–509.
- (15) Spanò, V.; Barreca, M.; Cilibrasi, V.; Genovese, M.; Renda, M.; Montalbano, A.; Galiotta, L. J. V.; Barraja, P. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein. *Molecules* **2021**, *26* (5), 1275.
- (16) Martina, M. G.; Sannio, F.; Crespan, E.; Pavone, M.; Simoncini, A.; Barbieri, F.; Perini, C.; Pesce, E.; Maga, G.; Pedemonte, N.; Docquier, J.; Radi, M. Towards Innovative Antibacterial Correctors for Cystic Fibrosis Targeting the Lung Microbiome with a Multifunctional Effect. *ChemMedChem.* **2022**, *17* (17), No. e202200277, DOI: 10.1002/cmdc.202200277.
- (17) Rylova, G.; Ozdian, T.; Varanasi, L.; Soural, M.; Hlavac, J.; Holub, D.; Dzubak, P.; Hajduch, M. Affinity-Based Methods in Drug-Target Discovery. *Curr. Drug Targets* **2015**, *16* (1), 60–76.
- (18) Davison, H. R.; Taylor, S.; Drake, C.; Phuan, P.-W.; Derichs, N.; Yao, C.; Jones, E. F.; Sutcliffe, J.; Verkman, A. S.; Kurth, M. J. Functional Fluorescently Labeled Bisthiazole $\Delta F508$ -CFTR Corrector Imaged in Whole Body Slices in Mice. *Bioconjugate Chem.* **2011**, *22* (12), 2593–2599.
- (19) Daina, A.; Zoete, V. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. *ChemMedChem.* **2016**, *11* (11), 1117–1121.
- (20) Daina, A.; Michielin, O.; Zoete, V. SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules. *Sci. Rep* **2017**, *7* (1), 42717.
- (21) Bahadir, O.; Saltan, G.; Ozbilgin, S.; Ergene, B. Affinity Chromatography and Importance in Drug Discovery. In *Column Chromatography*; Martin, D., Ed.; InTech, 2013. DOI: 10.5772/55781.
- (22) Bianchini, E.; Fanin, M.; Mamchaoui, K.; Betto, R.; Sandonà, D. Unveiling the Degradative Route of the V247M α -Sarcoglycan Mutant Responsible for LGMD-2D. *Hum. Mol. Genet.* **2014**, *23* (14), 3746–3758.